Abstract Library

#3055 Dynamics of Changes in Chromogranin A Concentration as a Prognostic Factor Radiopeptide Therapy in Neuroendocrine Tumours

Introduction: Chromogranin A (CgA) is a non-specific marker of neuroendocrine tumors (NET) and its significantly increased level is an unfavorable prognostic factor while the decrease in CgA during biotherapy with somatostatin analogs (SSA) correlates with the increase in profession free survival (PFS).

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Sygula A, Jurecka-Lubieniecka B, Hasse-Lazar K, Michalik B, Ledwon A,

Keywords: CgA, PRRT, prognosis,

#1533 Chromogranin A in the Follow-up of Digestive Neuroendocrine Neoplasms: Is It a Useful Biomarker?

Introduction: Chromogranin A (CgA) is the most frequently used biomarker in digestive neuroendocrine neoplasms (DNENs) but its real usefulness is still unclear

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author:

Authors: Merola E, Delle Fave G, Blankenstein O, Wiedenmann B, Pavel M,

Keywords: CgA, clinical usefulness, ≥ 50% increase,

#826 Correlation of Serum Chromogranin A Change with Radiographic Response in Patients with Non-Functioning Advanced Neuroendocrine Tumors

Introduction: Numerous studies have suggested that CgA determination may be useful for the diagnosis and follow-up of neuroendocrine tumors (NETs).

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author:

Authors: Cheng Y, Sun Z, Bai C, Ying H, Meng C,

Keywords: CgA change, radiographic response, nonfunctioning NETs,